Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $43.17.
A number of analysts recently issued reports on the company. Robert W. Baird initiated coverage on Spyre Therapeutics in a research report on Thursday, May 2nd. They issued an “outperform” rating and a $50.00 price target for the company. BTIG Research raised their target price on shares of Spyre Therapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Wells Fargo & Company upped their price target on shares of Spyre Therapeutics from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, May 13th. Finally, Evercore ISI initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They issued an “outperform” rating on the stock.
Get Our Latest Stock Analysis on SYRE
Spyre Therapeutics Trading Up 3.1 %
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.04. On average, research analysts forecast that Spyre Therapeutics will post -3.82 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in SYRE. Avoro Capital Advisors LLC purchased a new stake in Spyre Therapeutics in the 2nd quarter valued at about $43,238,000. Driehaus Capital Management LLC purchased a new position in shares of Spyre Therapeutics during the second quarter worth approximately $16,153,000. Farallon Capital Management LLC bought a new stake in shares of Spyre Therapeutics during the second quarter valued at approximately $15,658,000. Logos Global Management LP purchased a new stake in shares of Spyre Therapeutics in the second quarter valued at approximately $13,518,000. Finally, Affinity Asset Advisors LLC bought a new position in Spyre Therapeutics in the second quarter worth approximately $12,071,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
- Five stocks we like better than Spyre Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Options Trading – Understanding Strike Price
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- How to Evaluate a Stock Before Buying
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.